Biofil Chemicals & Pharmaceuticals Cash Flow
- Market cap
- ₹49.7 crore
- P/E
- 102.7
- P/B
- 2.30
- ROE
- 13.8%
- Dividend yield
- 1.20%
In the year ended Mar 2022, Biofil Chemicals & Pharmaceuticals generated ₹1,400 crore from operating activities, invested ₹600 crore and paid out ₹550 crore on financing activities. Net cash flow for the year was ₹250 crore. Free cash flow was ₹950 crore.
Biofil Chemicals & Pharmaceuticals cash flow statement
Financial years, newest first. Negative figures are cash outflows.
| Item | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Cash from operating activities | 1,400 | 0 | 2 | -2 | -1 |
| Cash from investing activities | -600 | 0 | 0 | 0 | 1 |
| Cash from financing activities | -550 | 0 | 0 | 0 | 3 |
| Net cash flow | 250 | 0 | 2 | -2 | 3 |
| Capital expenditure | — | — | — | — | — |
| Free cash flow | 950 | 0 | 2 | -2 | -1 |
Source: Company filings, in ₹ crore. Data as of 7 October 2026. How this data is compiled.
Biofil Chemicals & Pharmaceuticals cash flow — frequently asked questions
What is Biofil Chemicals & Pharmaceuticals' operating cash flow?
Biofil Chemicals & Pharmaceuticals' cash flow from operating activities was ₹1,400 crore in the year ended Mar 2022, from ₹0 crore in Mar 2023.
What is Biofil Chemicals & Pharmaceuticals' free cash flow?
Biofil Chemicals & Pharmaceuticals' free cash flow — operating cash flow minus capital expenditure — was ₹950 crore in Mar 2022.
How much did Biofil Chemicals & Pharmaceuticals spend on investing activities?
Net cash used in investing activities was ₹600 crore in Mar 2022. This covers capital expenditure, acquisitions and the purchase or sale of investments.
Same Data For Peers
Trade Biofil Chemicals & Pharmaceuticals With ATS
Track BIOFILCHEM live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.